Janux Therapeutics, Inc.

Janux Therapeutics, Inc. (JANX) priced its initial public offering on Jun 11, 2021 at $17.00 per share, within its $15.00–$17.00 range, raising $193.8M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $678.3M. BofA Securities was lead-left underwriter, joined by TD Cowen, Evercore ISI and H.C. Wainwright. Cooley advised the company and Latham & Watkins advised the underwriters.

Janux Therapeutics, Inc. is a biopharmaceutical company developing cancer therapeutics on its Tumor Activated T Cell Engager (TRACTr) platform. Its lead programs target PSMA, EGFR and TROP2, and all programs are at the preclinical or discovery stage.

Status

IPO

Ticker

JANX

Exchange

Nasdaq Global Market

Priced

Jun 11, 2021

IPO price

$17.00

Price range

$15.00–$17.00

Raised

$193.8M

Market cap at IPO price

$678.3M

First filed

May 19, 2021

Underwriters

BofA Securities, TD Cowen, Evercore ISI and H.C. Wainwright

Company counsel

Cooley

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.